This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XCHC Reports On 'American Drug War 2' National Theatrical Release On June 6, 2013; Interview With Kevin Booth

DALLAS, May 2, 2013  /PRNewswire/ -- The X-Change Corporation (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is cannabinoid extract-based cosmeceutical and nutraceutical solutions through its Phytiva brand product line, is proud to be part of the strategic team for 'American Drug War 2'. interviewed Mr. Booth about the film and its National Release on June 6, 2013.

The interview is available at

A trailer for 'AMERICAN DRUG WAR 2' can be seen at

Robert Kane, President of X-Change Corp., commented, "It is a privilege to be a part of some of the initial planning of the film and to have an appearance in the movie.  The Cash Hyde story, which is shared in the American Drug War 2 film, is one that is important and should be shared.  I encourage everyone interested in doing something positive in your community to go to and/or come out and support one of the events on June 6."

About 'American Drug War 2'

The film's distribution is being headed up by Gravitas Venture, a trend setting company that specializes in world-wide video-on-demand, as well as a theatrical release, through on-line start up "Basically anyone - anywhere can go to and request a screening in his or her own area at a favorite theater. It's a new concept revolutionizing the industry called 'Theaters on Demand.' Once your theater has sold approximately 50 tickets – your event is booked. It's free and allows fans not only to participate but also to earn a little extra to give back to local legalization efforts. Simply go to and become one of our hosts," stated Kevin Booth, who hopes to blanket the country with the film on June 6, 2013.


1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs